This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 09, 2012 8:30 am ET
Lisa Wilson -
Richard M. Smith - Chief Executive Officer, President, Chief Operating Officer and Director
Mary Jane Graves - Interim Chief Financial Officer and Treasurer
Brooks G. O'Neil - Dougherty & Company LLC, Research Division
Kyle D. Smith - Jefferies & Company, Inc., Research Division
Ladies and gentlemen, thank you for standing by. Welcome to BioScrip Fourth Quarter and Year End Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded, Friday, March 9, 2012. I would now like to turn the conference over to Lisa Wilson, Investor Relations for BioScrip. Please go ahead.
Good morning, and thank you for joining us today. By now, you should've received a copy of our press release issued this morning. If you have not received it, you may access it through the Investor Relations section at our website at BioScrip.com.
Rick Smith, President and Chief Executive Officer; and MJ Graves, Interim Chief Financial Officer and Treasurer, will host this morning's call.
The call may be accessed through our website at bioscrip.com. A replay will be available shortly after the call. Interested parties can access the replay by dialing (800) 633-8284 in the U.S. and (402) 977-9140 internationally and entering access code 21579469. An audio webcast will also be available under the Investor Relations section of the BioScrip website at bioscrip.com.
Before we get started, I would like to remind everyone that any statements made on the call today or in our press release that express a belief, expectation or intent, as well as those that are historical facts are considered forward-looking statements and are protected under the Safe Harbor provision of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to BioScrip today, and the company assumes no obligation to update statements as circumstances change.